Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Gastroenterology and hepatology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Autoimmune pancreatitis

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Overview

Distinguish autoimmune pancreatitis from pancreatic and biliary malignancy, recognise its systemic phenotypes, and use specialist-led immunosuppression while monitoring relapse, diabetes, obstruction and exocrine failure.

Autoimmune pancreatitis has two biologically different forms sharing a steroid-responsive pancreatic phenotype. Type 1 is the pancreatic expression of a systemic IgG4-related fibro-inflammatory condition and tends to relapse. Type 2 is usually pancreas-limited, has granulocytic epithelial lesions on histology and has an important association with ulcerative colitis.

The central safety problem is mimicry. Pancreatic cancer, cholangiocarcinoma, lymphoma and ordinary pancreatitis can overlap in symptoms, imaging and laboratory abnormalities. International diagnostic frameworks combine characteristic imaging, serology, other-organ involvement, histology and carefully observed response, but no convenient single feature should overrule discordant cancer evidence.

Management balances swift relief of obstruction with diagnostic integrity. Biliary sepsis needs immediate drainage and antimicrobial management; stable obstruction allows coordinated imaging and sampling. Immunosuppression should begin only when the multidisciplinary team has adequate evidence and a documented plan to verify response.

Key points

  • Autoimmune pancreatitis is a fibro-inflammatory pancreatic disorder: type 1 usually belongs to IgG4-related disease, whereas type 2 is not typically IgG4-driven and is associated with inflammatory bowel disease.
  • Painless obstructive jaundice, diffuse or focal pancreatic enlargement and duct narrowing can closely imitate pancreatic adenocarcinoma; diagnostic confidence must come from converging evidence.
  • A raised serum IgG4 supports type 1 disease but lacks adequate specificity to exclude cancer, and a normal result does not rule out type 2 autoimmune pancreatitis.
  • Cross-sectional imaging should assess the pancreas, biliary tree, vessels, nodes and other organs; focal disease or atypical features usually require endoscopic ultrasound and specialist tissue review.
  • Never use an informal steroid trial as the first diagnostic test for a pancreatic mass because transient improvement can delay definitive cancer diagnosis.
  • Corticosteroid induction often produces rapid biochemical and radiological improvement, but initiation, tapering and response checks belong in an experienced pancreatobiliary service.
  • Type 1 disease may involve bile ducts, salivary or lacrimal glands, kidneys, retroperitoneum, lymph nodes, lungs and aorta; examination should extend beyond the pancreas.
  • Long-term follow-up addresses relapse, biliary strictures, glucocorticoid harm, pancreatic exocrine insufficiency and diabetes rather than ending when jaundice resolves.

Aetiology

01

IgG4-related type 1 disease

Type 1 autoimmune pancreatitis is a pancreatic manifestation of IgG4-related disease and may accompany biliary, salivary, renal or retroperitoneal involvement.

02

Type 2 duct-centric disease

Type 2 autoimmune pancreatitis is usually pancreas-limited, has distinct granulocytic duct pathology and is associated with inflammatory bowel disease.

03

Immune dysregulation

The initiating cause remains uncertain; immune-mediated fibroinflammation rather than alcohol exposure or gallstones is central to both recognised subtypes.

Pathophysiology

  1. 1
    Lymphoplasmacytic inflammation

    Immune cells infiltrate pancreatic tissue and ducts, with IgG4-positive plasma cells prominent in type 1 disease.

  2. 2
    Swelling and duct narrowing

    Inflammation enlarges the pancreas and narrows pancreatic or distal bile ducts, producing obstructive jaundice or a mass-like appearance.

  3. 3
    Fibrosis and functional loss

    Persistent or recurrent inflammation causes fibrosis, atrophy and variable endocrine or exocrine pancreatic insufficiency despite an initial treatment response.

Clinical features and red flags

Pancreatic presentation

Painless jaundice, mild abdominal or back discomfort, weight loss or pancreatitis may accompany diffuse enlargement or a focal mass-like lesion.

IgG4 systemic pattern

Submandibular swelling, orbital or lacrimal disease, renal lesions, retroperitoneal fibrosis and long biliary strictures support type 1 disease when the whole pattern fits.

Type 2 context

A younger patient with inflammatory bowel disease and pancreatic inflammation may have type 2 disease despite normal IgG4 and absent extra-pancreatic IgG4 manifestations.

Imaging phenotype

Diffuse sausage-shaped enlargement, delayed enhancement, a capsule-like rim and long pancreatic-duct narrowing favour autoimmune inflammation, although focal abnormalities remain dangerous mimics.

Biliary disease

IgG4-related sclerosing cholangitis can produce obstructive jaundice through distal or hilar strictures and must be distinguished from primary sclerosing cholangitis and cholangiocarcinoma.

Functional consequences

Diabetes, steatorrhoea, weight loss and fat-soluble vitamin deficiency may result from inflamed or fibrotic pancreatic tissue even after obstruction improves.

Red flags requiring action

  • Fever, rigors, hypotension or confusion with jaundice indicates possible infected biliary obstruction and requires emergency antibiotics plus source-control planning.
  • Progressive focal mass enlargement, vascular invasion, metastases or substantial unexplained weight loss must keep pancreatic malignancy at the forefront despite elevated IgG4.

Investigations

  1. 01
    Pancreas-protocol CT and MRCPFirst step
    Why
    Define pancreatic morphology, duct strictures, biliary obstruction, vascular involvement and distant abnormalities.
    Interpretation and limitations
    Diffuse enlargement and long smooth narrowing are supportive, while a focal hypoenhancing mass, abrupt duct cut-off or metastatic pattern increases concern for cancer; overlap requires further evidence.
  2. 02
    Serum IgG subclasses
    Why
    Look for serological support for type 1 autoimmune pancreatitis and establish a treatment baseline.
    Interpretation and limitations
    Marked IgG4 elevation adds weight in a compatible phenotype but is neither specific nor mandatory; mild elevation occurs in malignancy and other inflammatory disorders.
  3. 03
    Endoscopic ultrasound tissue acquisition
    Why
    Assess a focal lesion and obtain architecture-preserving samples when malignancy remains plausible.
    Interpretation and limitations
    Core histology is more useful than cytology alone for lymphoplasmacytic inflammation, storiform fibrosis, obliterative phlebitis and IgG4-positive plasma cells; expert pathology correlation is essential.
  4. 04
    Liver profile and inflammatory markers
    Why
    Quantify obstruction, detect infection and provide objective measures for subsequent response.
    Interpretation and limitations
    Cholestatic improvement after treatment is supportive but not disease-specific; fever and rising inflammation with obstruction should be treated as cholangitis until assessed.

Differential diagnosis

01

Pancreatic cancer

Focal mass, vascular invasion, progressive weight loss or discordant response raises malignancy concern; serum IgG4 elevation alone cannot safely exclude cancer.

02

Chronic pancreatitis

Calcification, longstanding alcohol or smoking exposure and irreversible ductal change favour conventional chronic pancreatitis, though phenotypes can overlap.

03

PSC or cholangiocarcinoma

Multifocal biliary strictures favour PSC, while an irregular dominant lesion or malignant cytology raises cholangiocarcinoma concern over IgG4-related cholangitis.

Management

01MIMICMass or obstructive jaundice assessmentFirst stepImaging suggests autoimmune pancreatitis but pancreatic or biliary cancer remains possible.+
  1. 1Stabilise cholangitis, organ failure or severe obstruction first, using urgent biliary expertise when source control is needed.
  2. 2Acquire pancreatic-protocol imaging and review prior scans for evolution, duct configuration, metastases and other-organ manifestations.
  3. 3Discuss serology, endoscopic sampling and pathology in a specialist pancreatobiliary MDT before exposing a potentially resectable cancer to steroids.
  4. 4Record which diagnostic domains support autoimmune disease, which contradict it and exactly how response will be checked if treatment proceeds.
02INDUCESpecialist corticosteroid inductionA sufficiently secure diagnosis with symptomatic, obstructive or organ-threatening active disease.+
  1. 1

Complications

01

Biliary obstruction

Pancreatic swelling or associated cholangitis can obstruct bile flow, causing jaundice, pruritus and secondary infection requiring coordinated drainage assessment.

02

Diabetes and maldigestion

Inflammatory and fibrotic loss of pancreatic tissue can impair insulin secretion and digestive-enzyme delivery, causing diabetes, weight loss and deficiencies.

03

Relapsing systemic disease

Type 1 disease may recur in the pancreas or other organs, producing renal, retroperitoneal, salivary or biliary damage requiring long-term surveillance.

Monitoring and follow-up

  • Review jaundice, pain, weight and functional status together with liver tests soon after induction; response should be prompt enough to challenge an incorrect diagnosis.
  • Repeat cross-sectional or ductal imaging at a planned specialist interval to document reversal and ensure a presumed focal lesion has not progressed.
  • Monitor capillary glucose during induction and HbA1c longitudinally because pancreatic disease and corticosteroids both destabilise glycaemia.
  • Check weight, diet, stool pattern, fat-soluble vitamins and enzyme adherence where exocrine insufficiency is suspected or established.
  • During immunosuppression, follow full blood count, renal and liver function, infection history and agent-specific surveillance under the local shared-care arrangement.
  • Look actively for relapse in prior extra-pancreatic sites; serum IgG4 trends may contribute but should never be the sole trigger for retreatment.

Special situations

Two types differ

Type 1 links to systemic IgG4-related disease and relapse, while type 2 relies more heavily on histology and its inflammatory bowel disease association.

Steroid response has limits

Improvement can support a carefully constructed diagnosis only after malignancy work-up; it is unsafe as an unsupervised shortcut for a pancreatic mass.

Fibrosis may persist

A fixed stricture or organ deficit can remain after active inflammation settles, so not every abnormal scan or enzyme value warrants more immunosuppression.

Other organs offer clues

A safer biopsy target in kidney, node or salivary tissue may sometimes establish systemic disease without repeated sampling of a difficult pancreatic lesion.

Response must be objective

Pre-agreed biochemical and imaging endpoints protect against attributing analgesic improvement or fluctuating jaundice to successful immune treatment.

Common pitfalls

  1. 01

    Do not diagnose autoimmune pancreatitis solely from raised IgG4, because pancreatic cancer and other conditions can produce similar serology.

  2. 02

    Do not start corticosteroids before reasonable cancer exclusion and infection assessment, particularly when imaging shows a focal pancreatic mass.

  3. 03

    Do not assume all autoimmune pancreatitis is IgG4-related; type 2 disease has different associations, relapse behaviour and diagnostic evidence.

  4. 04

    Do not escalate immunosuppression for an isolated laboratory rise without checking symptoms, imaging, organ threat and alternative explanations.

  5. 05

    Do not forget enzyme failure and diabetes after radiological remission; damaged pancreatic function may need durable replacement and surveillance.

  6. 06

    Do not manage recurrent biliary obstruction as inflammation automatically; infection, cancer and mechanical stent failure remain competing causes.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Gastroenterology and hepatologyOriginal SBA

Evidence before steroids

A 68-year-old has painless jaundice, a focal pancreatic-head enlargement and a moderately raised serum IgG4. There are no known extra-pancreatic manifestations. What is the safest next approach?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Gastroenterology and hepatology topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG104 Pancreatitis recommendationsNational pancreatitis pathway and specialist referral context.
  • NICE NG85 Pancreatic cancer recommendationsRequired malignancy investigation and tissue-sequencing context.
  • Royal College of Pathologists gastrointestinal tissue pathwayPancreatic biopsy assessment, IgG4 staining and defining histology.
  • UCLH Pancreatobiliary serviceExample of UK tertiary multidisciplinary provision for complex pancreatobiliary and IgG4 disease.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
  • New visual symptoms, focal neurology, chest pain or renal deterioration may signal serious extra-pancreatic IgG4-related organ involvement needing urgent specialist assessment.
  • Severe hyperglycaemia, ketones, dehydration or reduced consciousness after starting corticosteroids requires immediate diabetes evaluation and acute treatment.
  • Worsening symptoms during a presumed steroid response should prompt diagnostic reset, repeat imaging and tissue review rather than automatic immunosuppression escalation.
  • 05
    Whole-person organ assessment
    Why
    Identify other IgG4-related sites through targeted history, examination, urinalysis and imaging review.
    Interpretation and limitations
    Concordant renal, salivary, orbital or retroperitoneal disease strengthens type 1 classification and may change treatment urgency or biopsy target.
  • 06
    Glucose and exocrine assessment
    Why
    Detect endocrine and digestive pancreatic dysfunction before and during treatment.
    Interpretation and limitations
    HbA1c, capillary glucose, weight trend, stool history and faecal elastase in an appropriate sample guide diabetes and enzyme support; symptoms alone underestimate impairment.
    • Screen for infection, diabetes risk, bone risk and steroid contraindications; address biliary sepsis before immunosuppression.
  • 2Start the specialist protocol and arrange early biochemical and clinical review rather than issuing an open-ended prescription.
  • 3Confirm objective radiological or ductal improvement at the planned interval; symptom relief alone is not adequate diagnostic validation.
  • 4Taper under the responsible service while monitoring glucose, mood, infection, blood pressure and recurrence of organ abnormalities.
    • 03RELAPSERecurrent or refractory diseaseReturn of pancreatic, biliary or extra-organ activity during taper or after remission.+
    1. 1Reconfirm true inflammatory relapse and exclude malignancy, stent dysfunction, infection and irreversible fibrotic damage.
    2. 2Map organs involved and severity, because a rising IgG4 value without clinical disease is not automatically an indication to treat.
    3. 3Discuss repeat steroid induction, steroid-sparing therapy or rituximab within an IgG4-experienced multidisciplinary service and current commissioning rules.
    4. 4Build maintenance surveillance around prior organ threats, treatment toxicity, diabetes, exocrine function and patient preferences.
    Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
    Induce remission in active autoimmune pancreatitis and clinically important IgG4-related organ disease.

    Prednisolone

    Use a specialist-defined oral induction dose followed by a structured taper based on objective response and relapse risk.

    Exclude untreated infection and adequately assess malignancy first; monitor glucose, mood, blood pressure, infection, eye and bone risks, and provide prevention according to exposure and patient factors.

    Provide steroid-sparing control for selected relapsing, refractory or organ-threatening type 1 disease.

    Rituximab

    Administer only through a specialist IgG4-related disease protocol with commissioned indication, screening and infusion supervision.

    Check hepatitis and infection status, vaccination timing, immunoglobulins and infusion risk; late infection and hypogammaglobulinaemia require longitudinal specialist monitoring.

    Replace deficient pancreatic enzymes during active inflammation or persistent exocrine failure.

    Pancreatin enzyme replacement

    Dose with each meal and snack, distribute capsules through eating, and titrate against intake, weight and maldigestion.

    Do not infer adequate treatment from less diarrhoea alone; assess technique, nutritional markers, acid environment and alternative causes of continuing symptoms.